# Data Sheet (Cat.No.T11162)

TargetMol

EGFR-IN-8

## Chemical Properties



CAS No. : 2407957-87-1

Formula: C32H23ClF3N7O4

Molecular Weight: 662.02

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

## Biological Description

| | |
|---|---|
| Description | EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC. |
| Targets(IC50) | EGFR,c-Met/HGFR |
| In vitro | In A549, PC9, H1975, CL68, and CL97cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97cells at different time intervals, with IC50 values ranging from 0.3 to 0.6μM and 0.2-0.5μM after 48 and 72h of treatment respectively[1]. |
| In vivo | EGFR-IN-8 (50,150mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner[1]. |

## Solubility Information

| | |
|---|---|
| Solubility | DMSO: < 1 mg/mL (insoluble or slightly soluble),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.5105 mL | 7.5526 mL | 15.1053 mL |
| 5 mM | 0.3021 mL | 1.5105 mL | 3.0211 mL |
| 10 mM | 0.1511 mL | 0.7553 mL | 1.5105 mL |
| 50 mM | 0.0302 mL | 0.1511 mL | 0.3021 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Dokla EME, et al. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur J Med Chem. 2019 Aug 9;182:111607.